RBOT_OUT_1 [2025-04-25 16:02:11 -0400] 5138 Bytes | 1385 tokens | Cum: 1385 tkns (17.31% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 4:02 PM on Fri Apr 25, 2025, and I'm firing up the spotlight on Vicarious Surgical (RBOT), moving from $6.65 to $8.47. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Vicarious Surgical (RBOT)
IPO: 2021-09-20 (3 Years Ago)
Market Cap: $31,965,945
Shares Outstanding: 5,280,000
Industry: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange: XNYS
Description: Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.

Here’s a list of headlines for Vicarious Surgical:

Apr-11-25 04:30PM - Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE
Mar-24-25 04:05PM - Vicarious Surgical Announces President Transition to Board Member Role
Mar-20-25 12:00PM - What Makes D8 (RBOT) a New Buy Stock
Mar-17-25 04:05PM - Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results
Mar-13-25 08:30AM - Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer
Mar-03-25 04:05PM - Vicarious Surgical to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 17, 2025
Feb-18-25 04:05PM - Vicarious Surgical Announces Planned Retirement of Chief Operating Officer
Dec-06-24 04:05PM - Vicarious Surgical Announces Departure of Chief Financial Officer
Nov-12-24 04:05PM - Vicarious Surgical Reports Third Quarter 2024 Financial Results
Oct-29-24 08:30AM - Vicarious Surgical to Report Third Quarter 2024 Financial Results on November 12, 2024
Aug-21-24 08:30AM - Vicarious Surgical to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug-12-24 04:05PM - Vicarious Surgical Reports Second Quarter 2024 Financial Results
Aug-07-24 08:30AM - Vicarious Surgical Announces New Hospital System Partnership with LSU Health New Orleans
Jul-29-24 04:10PM - Vicarious Surgical to Report Second Quarter 2024 Financial Results on August 12, 2024
Jun-10-24 04:15PM - Vicarious Surgical Announces Reverse Stock Split
May-22-24 07:23AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May-01-24 09:36AM - Vicarious Surgical Inc. (NYSE:RBOT) Q1 2024 Earnings Call Transcript
Apr-30-24 03:05AM - Vicarious Surgical Inc (RBOT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Cost ...
Apr-29-24 08:54PM - RBOT Stock Earnings: Vicarious Surgical Meets EPS for Q1 2024
Apr-29-24 08:54PM 04:05PM - Vicarious Surgical Reports First Quarter 2024 Financial Results
Apr-08-24 04:30PM - Vicarious Surgical to Report First Quarter 2024 Financial Results on April 29, 2024
Mar-04-24 04:10PM - Vicarious Surgical Reports Fourth Quarter and Full Year 2023 Financial Results

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-03-05T18:11:47Z - Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B2 - 2024-03-05T13:06:27Z - Why Paymentus Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
B3 - 2024-02-28T19:02:02Z - Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B4 - 2024-02-28T13:24:41Z - Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
B5 - 2024-02-06T13:16:16Z - Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
B6 - 2024-01-10T18:06:18Z - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Vicarious Surgical (RBOT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RBOT_OUT_3 [2025-04-25 16:02:12 -0400] 935 Bytes | 258 tokens | Cum: 1645 tkns (20.56% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T17:06:15Z - 12 Health Care Stocks Moving In Friday's Intraday Session - Coeptis Therapeutics (NASDAQ:COEP), Cycl...
A2 - 2025-04-12T03:46:27Z - Vicarious Surgical receives continued listing standard notice from NYSE...
A3 - 2025-04-11T20:31:38Z - Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE...
A4 - 2025-04-11T20:31:38Z - Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE...
A5 - 2025-04-11T20:46:00Z - Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RBOT_OUT_5 [2025-04-25 16:02:13 -0400] 1181 Bytes | 351 tokens | Cum: 1998 tkns (24.98% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Friday's Intraday Session - Coeptis Therapeutics (NASDAQ:COEP), Cyclacel Pharmaceuticals (NASDAQ:CYCC)**Date: 2025-04-25Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/45015979/12-health-care-stocks-moving-in-fridays-intraday-sessionGainers Jaguar Health JAGX stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. China SXT Pharmaceuticals SXTC shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. Cyclacel Pharmaceuticals CYCC shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. Vicarious Surgical RBOT stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. ENDRA Life Sciences NDRA stock rose 15.06% to $3.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RBOT_OUT_7 [2025-04-25 16:02:13 -0400] 1181 Bytes | 359 tokens | Cum: 2359 tkns (29.49% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): 97. The company's market cap stands at $2.1 million. Psyence Biomedical PBM stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. Losers Coeptis Therapeutics COEP shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. Summit Therapeutics SMMT stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. Intensity Therapeutics INTS shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. VYNE Therapeutics VYNE stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. Sutro Biopharma STRO stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. Instil Bio TIL stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. See Also: www.benzinga.com/money/best-hea

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RBOT_OUT_9 [2025-04-25 16:02:14 -0400] 1084 Bytes | 353 tokens | Cum: 2714 tkns (33.92% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): lthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

COEPCoeptis Therapeutics Holdings Inc$7.95-36.3%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum98.58Price TrendShortMediumLongOverviewCYCCCyclacel Pharmaceuticals Inc$0.23000.44%INTSIntensity Therapeutics Inc$0.5715-36.5%JAGXJaguar Health Inc$11.6444.4%NDRAENDRA Life Sciences Inc$3.9414.2%PBMPsyence Biomedical Ltd$0.516912.4%RBOTVicarious Surgical Inc$7.6815.5%SMMTSummit Therapeutics Inc$23.21-36.8%STROSutro Biopharma Inc$1.02-21.1%SXTCChina SXT Pharmaceuticals Inc$2.2039.2%TILInstil Bio Inc$15.06-23.2%VYNEVYNE Therapeutics Inc$1.46-22.3%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RBOT_OUT_11 [2025-04-25 16:02:16 -0400] 1105 Bytes | 284 tokens | Cum: 3000 tkns (37.50% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-11 8-K Item 7.01 Regulation FD Disclosure.

As required under NYSE rules, the Company issued a press release on April 11, 2025, announcing it had received the Notice from the NYSE described in Item 3.01. A copy of this press release is furnished hereto as Exhibit 99.1 to this Curr R...

S3 - 2025-03-24 8-K Item 7.01 Regulation FD.

On March 24, 2025, the Company issued a press release announcing Mr. Clarks transition from President to a member of its Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this...

S6 - 2025-03-17 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our CONS results of operations and finan...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RBOT_OUT_13 [2025-04-25 16:02:16 -0400] 1181 Bytes | 285 tokens | Cum: 3287 tkns (41.09% of 8k)
==========================================================================

Showing S1 (chunk 1 of 3): S1:
Item 7.01 Regulation FD Disclosure.

As required under NYSE rules, the Company issued a press release on April 11, 2025, announcing it had received the Notice from the NYSE described in Item 3.01. A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in, or incorporated into, this Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished under Item 7.01 of Form 8-K and shall not be deemed filed for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act regardless of any general incorporation language in such filings.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K includ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RBOT_OUT_15 [2025-04-25 16:02:17 -0400] 1181 Bytes | 249 tokens | Cum: 3538 tkns (44.22% of 8k)
==========================================================================

Showing S1 (chunk 2 of 3): es forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Companys ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSEs acceptance of such plan; the Companys ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; and risks arising from the potential suspension of trading of the Companys Class A common stock on the NYSE. The Companys actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein are forward-looking statements that re

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RBOT_OUT_17 [2025-04-25 16:02:18 -0400] 1033 Bytes | 210 tokens | Cum: 3750 tkns (46.88% of 8k)
==========================================================================

Showing S1 (chunk 3 of 3): flect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Companys control and are difficult to predict. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RBOT_OUT_19 [2025-04-25 16:02:26 -0400] 7597 Bytes | 1991 tokens | Cum: 5743 tkns (71.79% of 8k)
==========================================================================

This is our set of metrics for Vicarious Surgical.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+----------------------+
| Volume: 47,525 | Perf Month: 18.57% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 31.74K | Perf Quarter: -41.42% | Short Float: 4.34% | ROE: -87.40% |
+--------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 1.55 | Index: - | Short Ratio: 4.05 | ROI: -106.68% |
+--------------------+-----------------------+------------------------+----------------------+
| RSI (14): 64.40 | Market Cap: 50.00M | Short Interest: 0.13M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.76 | Shs Outstand: 5.27M | Beta: 1.49 | EPS Surprise: 9.63% |
+--------------------+-----------------------+------------------------+----------------------+
| SMA20: 43.95% | Shs Float: 2.96M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA50: -2.30% | Inst Own: 12.83% | Sales past 5Y: 0.00% | Earnings: Mar 17 AMC |
+--------------------+-----------------------+------------------------+----------------------+
| SMA200: -8.97% | Insider Own: 50.09% | Employees: 123 | |
+--------------------+-----------------------+------------------------+----------------------+
| Perf Week: 56.40% | Insider Trans: -0.20% | Debt/Eq: 0.30 | |
+--------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by Vicarious Surgical officers or majority shareholders (if available).

No transactions recorded.

Inside Trans: Vicarious Surgical Inc. (RBOT) by Khalifa Sammy (Chief Technology Officer) on 2025-03-21
- Class A Common Stock: 129 shares at $7.9707 (D) Footnote: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units that were granted on November 23, 2021.

Inside Trans: Vicarious Surgical Inc. (RBOT) by Sachs Adam David (CEO) on 2025-03-21
- Class A Common Stock: 161 shares at $7.9196 (D) Footnote: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units that were granted on November 23, 2021.

Inside Trans: Vicarious Surgical Inc. (RBOT) by Sachs Adam David (CEO) on 2025-03-03
- Class A Common Stock: 535 shares at $10.2791 (D) Footnote: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units that were granted on June 2, 2023.

Inside Trans: Vicarious Surgical Inc. (RBOT) by Mazzola John (Chief Operating Officer) on 2025-03-03
- Class A Common Stock: 264 shares at $10.2771 (D) Footnote: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units that were granted on June 2, 2023.

Inside Trans: Vicarious Surgical Inc. (RBOT) by Khalifa Sammy (Chief Technology Officer) on 2025-03-03
- Class A Common Stock: 276 shares at $10.2525 (D) Footnote: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units that were granted on June 2, 2023.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -63223000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.47
Average Volume: 20762.0
30-Day High: 8.47
30-Day Low: 5.08

[Detailed Financials: TTM 2024]
- Total Assets: $67,719,000.00
- Total Liabilities: $21,021,000.00
- Total Equity: $46,698,000.00
- Current Assets: $51,698,000.00
- Current Liabilities: $7,667,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-63,223,000.00
- Gross Profit: N/A
- Operating Income: $-66,555,000.00
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-43,085,000.00

[Detailed Financials: FY 2024]
- Total Assets: $67,719,000.00
- Total Liabilities: $21,021,000.00
- Total Equity: $46,698,000.00
- Current Assets: $51,698,000.00
- Current Liabilities: $7,667,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-63,223,000.00
- Gross Profit: N/A
- Operating Income: $-66,555,000.00
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-43,085,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Vicarious Surgical (RBOT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Vicarious Surgical.

2) MARKET_SCORE[]
This conversation was initiated because RBOT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RBOT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RBOT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RBOT to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Vicarious Surgical.

11) ETHICAL_RATING[]
Rate Vicarious Surgical’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Vicarious Surgical.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RBOT_IN_21 [2025-04-25 16:02:26 -0400] 126 Bytes | 29 tokens | Cum: 5983 tkns (74.79% of 8k)
==========================================================================

====================================
[2025-04-25 16:02:26] # Analysis Completed
Elapsed Time: 16.40 seconds